Scripintelligence - Loss widens at Proximagen on R&D spend 'that should have been higher'

Scrip Clinica Scrip Regulatory Affairs Scrip Clinical Research AnimalPharm

Advanced Search

Research & Development

Loss widens at Proximagen on R&D spend 'that should have been higher'
23 March 2011
Sukaina Virji

sukaina.virji@informa.com

Please Login to read the full article.

Not a subscriber? Subscribe to Scrip Request a FREE Trial

RELATED CONTENT

NEWS Scrip News

UCB execs take positive stance as big pharma peers wail about difficult environment
US Capitol Capsule: The SGR 'Doc Fix' Deal: Robbing Peter to pay Paul?
4SC steps up partnering efforts as key resminostat data comes in ahead of schedule
Greek pharma leader calls for industry unity and pragmatism after 7-hour "fight" with government

Other Informa News

ANALYSIS Other Informa Analysis

COMMENT Scrip Comment

CDx: more partnerships ahead, but more pharma awareness needed

Other Informa Comment

Dementia diagnosis remembered in UK research spending

FEATURES Scrip Features

DKSH highlights one-stop benefits as it builds Asia market expansion services

Other Informa Features

EVENTS

Bioavailability/Bioequivalence, Dissolution and Biowaivers

Today

Continental Zara Hotel, Budapest, Hungary

Sterilisation for Medical Devices

Today

Radisson Blu Royal Hotel, Dublin

Outsourcing Pharmaceutical Manufacture & Analytics

Today

Hotel Sofitel Hamburg Alter Wall

JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36

Home

Therapy Sector

Generics

Business

Policy & Regulation

Research & Development

International

Terms & Conditions

Scrip Regulatory Affairs

Scrip Clinical Research

Animal Pharm